PTC Therapeutics PTCT Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's accounts payable and other current liabilities (note 11)?
- PTC Therapeutics (PTCT) reported accounts payable and other current liabilities (note 11) of $313.05M in Q1 2026.
- How has PTC Therapeutics's accounts payable and other current liabilities (note 11) changed year-over-year?
- PTC Therapeutics's accounts payable and other current liabilities (note 11) decreased by 1.5% year-over-year, from $317.81M to $313.05M.
- What is the long-term trend for PTC Therapeutics's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), PTC Therapeutics's accounts payable and other current liabilities (note 11) has grown at a 9.5% compound annual growth rate (CAGR), from $242.17M to $381.27M.